Salzman & Co’s Elevance Health ELV Stock Holding History

Salzman & Co’s Portfolio ELV Stock Details ELV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,606	Closed	-$2.63M	–	2
2020 Q1	$2.63M	Buy	+11,606	New	+$3.16M	8.87%	5

Other funds holding ELV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Salzman & Co's ELV Position: Q2 2020 in Review

Salzman & Co sold out of Elevance Health (ELV) in Q2 2020, closing a stake of 11,606 shares — an estimated $2.63M sold.

Salzman & Co first reported a position in ELV in Q1 2020 and held it in 1 quarter. The position peaked at $2.63M in Q1 2020. 1,106 funds tracked by Wall St. Rank hold ELV as of Q2 2020.

Salzman & Co reported no remaining Elevance Health position as of Q2 2020 after selling out during the quarter.
Salzman & Co sold 11,606 Elevance Health shares in Q2 2020, an estimated $2.63M.
Salzman & Co first reported a position in Elevance Health in Q1 2020 and held it in 1 quarter.
Salzman & Co's Elevance Health position peaked at $2.63M in Q1 2020.
1,106 funds tracked by Wall St. Rank held Elevance Health as of Q2 2020.

Based on Salzman & Co's 13F filing for Q2 2020.